Please assess the completion status of the following clinical trial:

Trial Title: An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants who, in the opinion of the principal investigator or the investigator, are capable of understanding the content of the clinical research and complying with the research protocol requirements.~2. Participants who are able to sign and date the informed consent form and information sheet prior to the start of study procedures.~3. Participants diagnosed with type 2 diabetes mellitus.~4. Participants with a glycated hemoglobin (HbA1c) \[National Glycohemoglobin Standardization Program (NGSP value)\] value ≥ 6.5% and \< 8.5% at the start of the observation period (Day -2).~5. Participants who experience a ≤ ±1.0% change in HbA1c (NGSP value) at the start of the observation period (Day -2) as compared with an HbA1c value obtained during the preceding 6 weeks.~6. Participants receiving stable dietetic therapy and exercise therapy (if performed) for ≥ 4 weeks before the start of the observation period.~7. Participants, who in the opinion of the principal investigator or the investigator, does not have to change (including discontinuation or interruption) 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors or add new HMG-CoA reductase inhibitors during treatment period.~8. Men or women aged 20 years or older at the time of informed consent.~Exclusion Criteria:~1. Participants who received anti-diabetic medications within 4 weeks prior to the start of the observation period.~2. Participants who have changed (including discontinuation or interruption) HMG-CoA reductase inhibitors or received new HMG-CoA reductase inhibitors ≤ 4 weeks before the start of the observation period.~3. Participants with clinically evident hepatic dysfunction (e.g., aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥ 2.5-fold the upper limit of normal at the start of the observation period \[Day -2\]).~4. Participants with moderate renal dysfunction, severe renal dysfunction or renal failure (e.g., creatinine clearance \< 50 mL/min or serum creatinine \> 1.4 mg/dL in men or \> 1.2 mg/dL in women \[equivalent to the creatinine clearance for persons aged 60 years with a body weight of 65 kg\] at the start of the observation period \[Day -2\]).~5. Participants with severe heart disease, cerebrovascular disorder, or severe pancreatic, hematologic or other diseases.~6. Participants with a history of gastric or small intestinal resection.~7. Participants with proliferative diabetic retinopathy.~8. Participants warranting insulin therapy for glycemic control (e.g., participants with severe ketosis, diabetic coma or precoma, type 1 diabetes mellitus, severe infection, perioperative participants, or serious trauma).~9. Participants with a history of hypersensitivity or allergy to DPP-4 inhibitors.~10. Participants who experience an allergic reaction to metal during CGM at the start of the observation period (Day -2).~11. Participants with any malignant tumors.~12. Habitual drinkers whose average daily alcohol consumption is \> 100 mL.~13. Participants who have any contraindications for the study drug or are taking any contraindicated concomitant drugs listed in the package insert.~14. Participants anticipated to require any prohibited concomitant medications during the study period.~15. Participants who are day and night lifestyle reversal.~16. Participants participating in any other clinical studies at the time of informed consent for this study.~17. Pregnant women, nursing mothers, women who are possible pregnant, or women who plan to become pregnant.~18. Other participants who are considered inappropriate for participation in this study in the opinion of the principal investigator or investigator.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Trelagliptin 100 mg group (Type: EXPERIMENTAL): Trelagliptin 100 mg once weekly taken orally before breakfast
- Alogliptin 25 mg group (Type: EXPERIMENTAL): Alogliptin 25 mg once daily taken orally before breakfast

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete